Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy

JAMA Ophthalmol. 2014 Jul;132(7):899-901. doi: 10.1001/jamaophthalmol.2014.409.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged
  • Autoantibodies / blood
  • Autoantigens / immunology
  • Electroretinography
  • Erlotinib Hydrochloride
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Infusions, Intravenous
  • Isoxazoles / administration & dosage
  • Isoxazoles / adverse effects*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Night Blindness / chemically induced
  • Night Blindness / immunology
  • Night Blindness / physiopathology*
  • Paraneoplastic Syndromes, Ocular / chemically induced
  • Paraneoplastic Syndromes, Ocular / immunology
  • Paraneoplastic Syndromes, Ocular / physiopathology*
  • Phosphopyruvate Hydratase / immunology
  • Quinazolines / administration & dosage
  • Resorcinols / administration & dosage
  • Resorcinols / adverse effects*
  • Retina / drug effects
  • Tomography, Optical Coherence
  • Visual Acuity / physiology

Substances

  • 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
  • Autoantibodies
  • Autoantigens
  • HSP90 Heat-Shock Proteins
  • Isoxazoles
  • Quinazolines
  • Resorcinols
  • Erlotinib Hydrochloride
  • Phosphopyruvate Hydratase